Company NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 10:44:37 14/05/2024 pm IST			5-day change	1st Jan Change
4 ^USD	-0.74%		+4.17%	+8.21%

09/05	NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/05	Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target	MT

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.

Number of employees: 8

Managers	Title	Age	Since
Hyung-Heon Kim CEO	Chief Executive Officer	47	09/21/09
Marshall H. Woodworth DFI	Director of Finance/CFO	66	27/23/27

Members of the board	Title	Age	Since
D. Strickland BRD	Director/Board Member	77	27/22/27
Andrew Koven CHM	Chairman	66	09/21/09
Mark Glickman BRD	Director/Board Member	58	11/23/11
Michael Salsbury BRD	Director/Board Member	74	31/19/31
Jason Groves BRD	Director/Board Member	52	31/19/31
James Tursi BRD	Director/Board Member	59	01/11
Hyung-Heon Kim CEO	Chief Executive Officer	47	09/21/09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,906,002	1,880,689 ( 38.33 %)	0	38.33 %

Name	Equities	%	Valuation
DONG-A ST CO., LTD. 57.15 %	2,803,699	57.15 %	9 M $
Hudson Bay Capital Management LP 0.8493 %	41,666	0.8493 %	127 498 $
Next Edge Capital Corp. 0.7378 %	36,198	0.7378 %	110 766 $
Marshall H. Woodworth 0.6828 %	33,496	0.6828 %	102 498 $
Vanguard Group, Inc. (Subfiler) 0.5711 %	28,020	0.5711 %	85 741 $
E&Investment, Inc. 0.5110 %	25,069	0.5110 %	76 711 $
Geode Capital Management LLC 0.4220 %	20,703	0.4220 %	63 351 $
Na Yeon Kim 0.2704 %	13,266	0.2704 %	40 594 $
G1 Execution Services LLC 0.2552 %	12,518	0.2552 %	38 305 $
Andrew Koven 0.1115 %	5,469	0.1115 %	16 735 $

NeuroBo Pharmaceuticals, Inc.

545 Concord Avenue Suite 210

02138, Cambridge

http://www.neurobopharma.com

address NeuroBo Pharmaceuticals, Inc.(NRBO)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.03 USD

Average target price

36.5 USD

Spread / Average Target

+805.71%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NEUROBO PHARMACEUTICALS, INC.	+8.21%	19.77M
VERTEX PHARMACEUTICALS INCORPORATED	+4.04%	111B
REGENERON PHARMACEUTICALS, INC.	+11.49%	105B
BIONTECH SE	-12.66%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.43%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+2.90%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.81%	12.45B

Bio Therapeutic Drugs